cut_t_wires_banner.gif
Google Search
23711208 Visitors
 HOME
 Obituaries 8-11
 Yahoo Comic Strips
 Daily Crossword
 Today's Trivia
 Daily Horoscopes
GAMES
 ARCADE
 Sheepish
 Shootem In
 Master Solitaire
 Trap Shooter
 Crypt Raider
 Pharaoh's Tomb
 HANGAROO
Area Towns
 EMERGENCY #s
 Berryville
 Eureka Springs
 Green Forest
 Holiday Island
Local Schools
 Berryville
 Clear Spring
 Eureka Springs
 Green Forest
Nat/Int News
 Top Stories
 World
 Business
 Sports
 Entertainment
 Health
 Politics
 Technology
 Science
 Opin/Editorial
 Oddly Enough

Newsfeeds

World News
Wed, 12 Aug 2020 09:41
Yahoo News - Latest News &Headlines
Israel says it foiled hackers targeting defense industry
Global Chemical Mechanical Planarization Industry
Trump congratulates QAnon supporter Greene on Georgia winPresident Donald Trump on Wednesday tweeted support for congressional candidate Marjorie Taylor Greene, a supporter of the far-right QAnon conspiracy theory who’s been criticized for racist comments, following her Republican primary victory in Georgia. Greene, a businesswoman and political newcomer, beat neurosurgeon John Cowan in a primary runoff Tuesday in Georgia’s deep-red 14th Congressional District, which stretches from the outskirts of metro Atlanta to the rural northwest corner of the state.
Trump congratulates QAnon supporter Greene on Georgia win
Biden, Harris to make unusual campaign debut in virus eraJoe Biden is making his first appearance with newly chosen running mate Kamala Harris on Wednesday, betting that the California senator’s historic profile and confrontational style against President Donald Trump will boost Democrats’ efforts to oust the Republican president amid cascading national crises. The former primary rivals will appear at a high school near Biden’s Delaware home to discuss their shared vision for how to defeat Trump and then lead the country through a pandemic, its economic fallout and a long-simmering reckoning with systemic racism. Harris and Biden then will sit down together for an online fundraiser designed to let even small donors get a fresh glimpse of what the Democratic presidential ticket will look like together.
Biden, Harris to make unusual campaign debut in virus era
U.S. Goes It Alone to Keep Weapons Out of Iran
Mauritius oil spill: Rush to pump out oil before ship breaksThe MV Wakashio ran aground on a coral reef on 25 July, and has leaked oil into the ocean.
Mauritius oil spill: Rush to pump out oil before ship breaks
U.S. Aims To Extend U.N. Arms Embargo On IranThe U.S. is aiming to extend a United Nations arms embargo on Iran — indefinitely. The embargo prohibits Iran from buying and selling conventional weapons. The U.S.' new proposed resolution reportedly recommends extending the ban until the "council decides otherwise."
U.S. Aims To Extend U.N. Arms Embargo On Iran
U.S. Aims to Extend U.N. Arms Embargo on IranThe U.S. is aiming to extend a United Nations arms embargo on Iran — indefinitely. The embargo prohibits Iran from buying and selling conventional weapons. The U.S.' new proposed resolution reportedly recommends extending the ban until the "council decides otherwise."
U.S. Aims to Extend U.N. Arms Embargo on Iran
Trump v. Putin: A Vaccine Manhood ContestAmerican scientists hope this is one time that President Donald Trump really does believe it is all just a Russian hoax.As President Vladimir Putin of Russia triumphantly declared on Tuesday that his country had produced the world's first coronavirus vaccine, public health experts in the United States worried that Trump would feel compelled to compete in a pharmaceutical manhood contest by hastily rolling out his own vaccine even before it is fully tested."I am sure that this will give him more impetus to push U.S. R&D and FDA to move more quickly," Margaret Hamburg, a Food and Drug Administration commissioner under President Barack Obama, said, referring to research and development. "If he believes that testing causes cases, I suspect he may believe that if you don't test a vaccine or drug, they must be OK."The announcement in Moscow roiled the international quest to stop the pandemic in what had already developed into a geopolitical race among the world's biggest powers. The Russian vaccine, approved without the sort of extensive trials typically required in the West, may work, American scientists said. But if it does not, the rushed process could pose dangers not just for Russians but for many others if Trump seeks to match the supposed achievement prematurely.The search for a vaccine has already been caught in a whirlwind of pressures as the Trump administration scrambles to develop a drug to combat a virus that has killed more than 164,000 Americans. Two pharmaceutical companies have moved to Phase 3 trials in the United States, the final stage of testing before a vaccine can be approved. But scientists have expressed concern that the trials would be short-circuited by Trump's desire for a political win before the general election Nov. 3.The White House has said that data, not politics, will govern the decision to approve a vaccine, although Trump has repeatedly linked his Operation Warp Speed to the campaign calendar. He has suggested that a vaccine could be rolled out by Election Day even though scientists said it would take until early next year to complete the trials."We're doing very well in everything including corona, as you call it," Trump said in an interview Tuesday with radio host Hugh Hewitt. "But let me just tell you, we're getting to an end. We're getting to, and the vaccines are ready to rock. We're going to be very close to a vaccine. We're ready to distribute."At a news briefing later in the day, the president offered no comment on Russia's announcement but made a point of boasting about the "tremendous progress" on an American vaccine and asserted that "we're moving very close to that approval.""Operation Warp Speed is the largest and most advanced operation of its kind anywhere in the world and anywhere in history," he said, his competitive juices on display.Putin saw no need to wait for more expansive testing in Russia, where the medical system is not considered as rigorous as in the United States, despite the prospect that it may not work as advertised or may even prove unsafe. But in doing so, he put Trump in an awkward position given the friendship between the two men."Judging from Trump's history of seeming deference to Putin as well as an ongoing personal desire for a 'win,' Trump may wish to replicate at home what he sees as a Russian vaccine triumph," said Monica Schoch-Spana, a senior scholar at the Johns Hopkins Center for Health Security.David Kramer, a Russia scholar at Florida International University and a former assistant secretary of state under President George W. Bush, said Trump should use the moment to put his desire for better relations with Russia to the test."Aside from arms control, fighting the virus would be one issue where we and Russia should work together and not be another source of competition," he said. "The speed with which the Russians have found a vaccine has to raise concerns, however, and risks exacerbating the level of distrust between our two sides if it does not work or even does harm."The vaccine race comes at a time when Washington is already engaging in a new debate over how to recalibrate relations between the two powers after the election. A group of 103 former Cabinet secretaries, ambassadors and other officials from Democratic and Republican administrations published an open letter last week in Politico arguing for an effort to "put the relationship on a more constructive path."Another group of former officials, this one with 33, led by Kramer, published its response Tuesday rejecting a new "reset" and arguing that Putin's regime poses "a threat to American interests and values, requiring strong pushback."The relationship has been dominated by the aftermath of the 2016 election, when Russia intervened in the American campaign to help Trump, according to intelligence agencies and a special counsel investigation. While no charges were brought alleging a criminal conspiracy, Trump has at times rejected even that Russia played a role, calling it a hoax.Just last week, U.S. intelligence agencies reported that Russia was still trying to intervene in American elections to help reelect Trump, a conclusion that the president likewise instantly rejected. "I think that the last person Russia wants to see in office is Donald Trump because nobody has been tougher on Russia than I have, ever," he said at a briefing for reporters.Told that was not what the intelligence agencies were finding, Trump snapped, "Well, I don't care what anybody says."He defended himself further on Tuesday when Hewitt asked who had been tougher on Russia, Trump or Obama. "By a factor of 50, me, OK?" Trump said, arguing that he built up the U.S. military and sent weapons to Ukraine for its continuing conflict with Russia.As he often does, however, Trump laced his answer with factual fallacies. He boasted that he sent Javelin anti-tank weapons to Ukraine when Obama would not, which is true. But what Trump did not say was that his administration barred the Ukrainians from actually using the Javelins and mandated that they be kept locked up far from the battlefront.The president likewise boasted that "I got NATO to pay $400 billion a year more to protect themselves against Russia." That is not true. NATO has projected that the allies will increase military spending by a cumulative $400 billion from 2016 to 2024, meaning over eight years, not each year. Similarly, Trump said he "spent $2.5 trillion" on the U.S. military, but that credits him with every dollar spent on defense over three years and then some, not just the increases he helped push through.It is true that his administration has taken aggressive action to counter Russia at times -- including sanctions, diplomatic expulsions and modest troop deployments to Eastern Europe -- but Trump has left the tough talk to his subordinates and rarely if ever has a word of criticism of Putin, whose leadership and strength he has publicly praised. Indeed, Trump has spoken repeatedly with Putin in recent months without once raising intelligence reports that Russia has paid bounties to Afghan fighters to kill U.S. soldiers. Trump dismissed the reports from his own administration as "fake news."In a separate string of Twitter messages Tuesday, Trump disputed the notion that he trusted Putin more than U.S. intelligence agencies, but he then proceeded to explain why he would doubt his own country's security apparatus, pointing back to his first encounter with veteran intelligence officials that he later came to consider his enemies."John Bolton, one of the dumbest people I've met in government and sadly, I've met plenty, states often that I respected, and even trusted, Vladimir Putin of Russia more than those in our Intelligence Agencies," Trump wrote, referring to his own former national security adviser."While of course that is not true," he continued, "if the first people you met from so called American Intelligence were Dirty Cops who have now proven to be sleazebags at the highest level like James Comey, proven liar James Clapper, &perhaps the lowest of them all, Wacko John Brennan who headed the CIA, you could perhaps understand my reluctance to embrace!"This article originally appeared in The New York Times.(C) 2020 The New York Times Company
Trump v. Putin: A Vaccine Manhood Contest
Amid crises, UNICEF USA launches program to help kids in USFor more than 70 years, the U.S. affiliate of UNICEF has supported the global work of that U.N. agency, most of it focused on aiding children in developing countries. On Wednesday, amid overlapping domestic crises, UNICEF USA announced its first major program supporting children in the United States. Michael Nyenhuis, UNICEF USA’s president and CEO, said his agency will be investing $1 million this year on an initiative to help U.S. cities become more child-friendly.
Amid crises, UNICEF USA launches program to help kids in US
A COVID-19 vaccine needs the public's trust – and it's risky to cut corners on clinical trials, as Russia isRussia’s announcement that a fast-tracked COVID-19 vaccine is registered there, with plans for quick distribution in the general population this fall, is being condemned by scientists worldwide.Findings from scientific studies of this vaccine, named “Sputnik V,” are not available. Large safety and efficacy trials are not yet complete. But despite only two months of testing in people, Russian President Vladimir Putin called the vaccine “quite effective” and it’s received regulatory approval.In other places, notably the United States, China and the European Union, even as researchers rush to develop vaccines, they continue to publish studies of these vaccines at a more measured pace than is happening in Russia.As an epidemiologist who studies vaccine hesitancy and vaccine-preventable disease, I’m concerned about this news from Russia. After essential workers and high-risk groups are vaccinated, I would want to be among the first in line for an approved COVID-19 vaccine, but the medical research system must make sure any vaccine is safe and effective before distributing it to the population at large. Clinical trials have a valuable roleBefore any drug, vaccine or medical device is licensed for use in the general population, it needs to go through several rounds of large-scale testing. These studies are designed to make sure the intervention is safe and effective, and to understand what the appropriate dosage will be.Under normal conditions, the research required to bringa vaccine to market can take decades. For example, before the HPV vaccine was licensed in the U.S. in 2006, a phase III clinical trial enrolled 18,644 participants in 2004-2005, a phase II clinical trial had enrolled 1,113 participants in 2000, and the laboratory studies that led to a vaccine candidate had been published in the early 1990s.In the face of the coronavirus pandemic, scientists around the globe are focusing their efforts on developing a COVID-19 vaccine. They’re working at an unprecedented pace to move through the necessary clinical trials to end up with a safe and effective vaccine. One of the most time-consuming parts of clinical trials is enrolling participants, and pharmaceutical companies have sped up this process by lining up volunteers early, obtaining important baseline data from them even before a vaccine candidate is available. Problems if the vaccine is released too earlyCarefully conducted clinical trials are necessary to identify any problems with the vaccine. For example, studies of a new type of measles vaccine in the early 1990s found that it was detrimental to baby girls, and so it was never licensed to the general population. The existing measles or measles-mumps-rubella vaccine available in the U.S. and other countries is highly safe and effective. It could also be that the vaccine is not effective in some categories of people. Phase I and II clinical trials have small sample sizes and may not include individuals from high-risk groups. For example, a recently published phase II clinical trial of a COVID-19 vaccine excluded obese people, those with chronic diseases and pregnant women. However, these are all groups that should be able to get the vaccine in the future. More studies, including phase III trials, are necessary to discover ifthe vaccine works in the general population. Preliminary results should be available by the end of 2020.The concern is that by introducing the vaccine early, without adequate testing of safety, effectiveness and dosing, the population may be presented with a vaccine which is not safe or not effective, and with little information on which vaccine schedule is best.Food and Drug Administration Commissioner Dr. Stephen Hahn has said the FDA will not “cut corners” in approving a COVID-19 vaccine in the U.S. despite an accelerated program, dubbed Operation Warp Speed. Rushing to marketBut is there ever an ethical reason to release a vaccine early, even without going through all phases of clinical trials?Although it would be wonderful to get a vaccine into the population quickly, there could be substantial downsides if researchers and manufacturers cut corners. Imagine a vaccine that oftenhad serious side effects that weren’t caught in small trials before it was widely administered.[Research into coronavirus and other news from science Subscribe to The Conversation’s new science newsletter.]An untested vaccine wouldn’t just harm the people vaccinated. If negative perceptions about the safety or efficacy of a COVID-19 vaccine spread throughout the population, it could limit how many people are willing to get the shot and perpetuate disease transmission.Trust in vaccination programs is crucial. Russia, in fact, provides an important historical example. In the 1990s, trust in the country’s public health system rapidly decreased, and rates of diphtheria-tetanus-pertussis vaccination fell as a result. A large outbreak of diphtheria then spread through eastern Europe, leaving over 4,000 people dead.Hasty rollout of a COVID-19 vaccine could prime people not only to not trust the COVID-19 vaccine, but also to doubt vaccination and public health systems as a whole. Vaccinations should be developed by impartial scientists and evaluated by nonpartisan government officials. By cutting red tape, procedures can be prioritized and sped up, but they must not be skipped.This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts.Read more: * How effective does a COVID-19 coronavirus vaccine need to be to stop the pandemic? A new study has answers * What needs to go right to get a coronavirus vaccine in12-18 monthsAbram L. Wagner receives funding from the NIH and NSF.
A COVID-19 vaccine needs the public's trust – and it's risky to cut corners on clinical trials, as Russia is
More tribal clashes in Sudanese port city; death toll at 25
Iran's Rouhani hopeful US arms embargo push will failIran's President Hassan Rouhani expressed "great hopes" Wednesday that a US bid to extend an arms embargo on his country will fail, warning of consequences if the UN Security Council backs it. Rouhani's remarks came after Iran's ambassador to the United Nations said the US would have to redraft its proposed resolution on the issue after being "rebuffed" by Security Council members. The ban on selling weapons to Iran is set to be progressively eased from October under the terms of Resolution 2231, which blessed the Iran nuclear deal that world powers agreed in July 2015.
Iran's Rouhani hopeful US arms embargo push will fail
Trump adds grandiose promises to campaign pitchPresident Trump is promising voters he will replace the Affordable Care Act, forge a new Iran nuclear deal, end the payroll tax and achieve other ambitious goals within weeks if reelected. His ability to deliver on them is close to zero.
Trump adds grandiose promises to campaign pitch
The daily business briefing: August 12, 2020

 INSURANCE
Browser Prefs
Add to Favorites
Make Home Page
Arcade Hi Scores
Snake:
15000
By: I DID NOT CHEAT
Tetris:
2147483647
By: PLAYED BY MASTER
Asteroids:
2147483647
By: WORLD RECORD
Invaders:
2147483647
By: YOU DID HACK IT
Pacman:
200000
By: GAME OVER
ABC News
 World News
 U.S. News
 Politics
 MONEYScope
 SciTech
 Entertainment
 Travel
 Health
 Relationships
 GMA
 Nightline
 Primetime
 20/20
 WNT

NWADN.com disclaims all liability or responsibility for any loss or damage that may result from the action or
failure to act or not act by any person in regards to any information provided within this website.